EUCTR2016-000101-37-GR
Active, not recruiting
Phase 1
A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (lulizumab) or BMS-986142 in Subjects with Moderate to Severe Primary Sjögren's Syndrome - POC H2H study
Conditionssubjects with moderate to severe Sjögren's syndromeMedDRA version: 19.1Level: LLTClassification code 10040766Term: Sjogren's diseaseSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 19.1Level: PTClassification code 10040767Term: Sjogren's syndromeSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 19.1Level: LLTClassification code 10042846Term: Syndrome Sjogren'sSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 19.1Level: LLTClassification code 10040765Term: Sjogren'sSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 19.1Level: PTClassification code 10048676Term: Sjogren-Larsson syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Immune System Diseases [C20]
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- subjects with moderate to severe Sjögren's syndrome
- Sponsor
- Bristol-Myers Squibb International Corporation
- Enrollment
- 160
- Status
- Active, not recruiting
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Age 18\-70 years old
- •\- Subjects diagnosed or classified as having moderate to severe primary Sjögren’s syndrome based on the 2015 ACR\-EULAR Classification Criteria
- •\- ESSDAI \= 5 including disease activity (any score \> 0\) in at least one of the following domains: Glandular, Articular, Hematological, Biological, Lymphadenopathy
- •\- Positive anti\-SS\-A/Ro or anti\-SS\-B/La autoantibody
- •\- Unstimulated whole saliva secretion \> 0\.01 ml/min
- •\- Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug and must not be pregnant or breastfeeding. Male and female subjects must be willing to adhere to protocol\-mandated highly effective contraception for the duration of the study and for the protocol\-specified follow up period. Hormone\-based contraceptive methods are not permitted.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 128
Exclusion Criteria
- •\-Secondary Sjögren's syndrome or the presence of any other systemic autoimmune disease (eg, RA, SLE, multiple sclerosis)
- •\-Very severe primary Sjögren's syndrome or severe complications of primary Sjögren's syndrome at the time of the screening visit
- •\-Active systemic bacterial (including tuberculosis), viral or fungal infection, or evidence of prior or current Hepatitis B or C, HIV infection, latent bacterial, viral or fungal infections
- •\-Any significant concurrent medical condition at the time of screening or baseline visit
- •\-Use of methotrexate, cyclophosphamide, cyclosporine, tacrolimus, azathioprine, mycophenolate mofetil (MMF) or leflunomide within 12 weeks of screening visit
- •\-Previous treatment with other biologics either marketed or in development within 6 months prior to screening visit
- •\-Treatment started or an unstable dose of hydroxychloroquine within
- •8 weeks of screening visit.
- •\-Oral corticosteroids \> 10 mg/day within 14 days of dosing (Day 1\), corticosteroid therapy \= 1 mg/kg during the 4 weeks preceding enrollment, or intravenous, intramuscular or intra\-articular corticosteroids within 4 weeks of screening visit.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (lulizumab) or BMS-986142 in Primary Sjögren's SyndromeEUCTR2016-000101-37-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO120
Active, not recruiting
Phase 1
A randomized, blinded clinical study comparing the combination durvalumab and olaparib to durvalumab alone for patients with advanced bladder cancernresectable Stage IV Urothelial CancerMedDRA version: 20.0Level: LLTClassification code 10022880Term: Invasive bladder cancer stage IVSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2017-004556-27-ESAstraZeneca AB154
Recruiting
Not Applicable
A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate theEfficacy and Safety of BMS-931699 (lulizumab) or BMS-986142 in Subjects with Moderate to Severe Primary Sjogren´s Syndrome-M350 Sicca syndrome [Sjogren]Sicca syndrome [Sjogren]M350PER-035-16BRISTOL MYERS SQUIBB COMPANY,1
Active, not recruiting
Not Applicable
A Phase II, Randomized, Multi-Centre, Double-Blind, Placebo-Controlled Trial of HMPL-004 in Patients with Mild to Moderate Active Ulcerative Colitis with or without MesalamineEUCTR2007-005166-12-DEHutchison MediPharma Enterprises Limited210
Not yet recruiting
Phase 2
A Study of Tobemstomig/RO7247669 Combined With Nab-Paclitaxel Compared With Pembrolizumab Combined With Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast CancerCancerPACTR202404480503746Hoffmann La Roche160